Your browser doesn't support javascript.
loading
Serum thrombin-activatable fibrinolysis inhibitor levels and its relation with pathogenesis and bleeding and prognosis in patients with Crimean Congo hemorrhagic fever.
Altin, Nilgun; Altay, Fatma Aybala; Albayrak, Murat; Sahingoz, Seyda Ozdemir; Sencan, Irfan.
Affiliation
  • Altin N; Department of Infectious Diseases and Clinical Microbiology, Diskapi Yildirim Beyazit Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Altay FA; Department of Infectious Diseases and Clinical Microbiology, Diskapi Yildirim Beyazit Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Albayrak M; Department of Hematology University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
  • Sahingoz SO; Department of Biochemistry University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
  • Sencan I; Department of Infectious Diseases and Clinical Microbiology, Diskapi Yildirim Beyazit Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
J Med Virol ; 95(1): e28182, 2023 01.
Article de En | MEDLINE | ID: mdl-36175009
ABSTRACT
Crimean-Congo hemorrhagic fever (CCHF) is a viral hemorrhagic fever, which is common in Turkey and globally. The pathogenesis of coagulation disorders, which is seen in viral hemorrhagic fevers remains to be elucidated. Thrombin-activatable fibrinolysis inhibitor (TAFI) has a key role in this process In this study, we aimed to evaluate whether TAFI levels contributed to bleeding and whether it is related to prognosis in CCHF patients. Eighty-four patients older than 15 years of age, who were admitted to our hospital who had positive immunoglobulin M (enzyme-linked immunosorbent assay [ELISA]) and/or polymerase chain reaction test results for CCHF between 2009 and 2010, were included in the study. The control group included 30 healthy adults. The plasma TAFI levels were compared between patients and controls, and also between patients with bleeding and no bleeding, and between patients with mild-moderate and severe disease. The mean TAFI levels were lower in patients (mean 87.82 ng/ml, median 61.69 ng/ml (interquartile range [IQR] 30.49-537.95) than controls (mean 313.5 ng/ml with a median 338.5 ng/ml (IQR 182-418). However, median TAFI levels were significantly higher in patients with bleeding compared to those without bleeding (78.99 and 50.28 ng/ml, respectively; p = 0.032). Median IQR TAFI levels were similar between patients with mild-moderate and severe disease (64.72 (41.37-113.85), and, 58.66 (42.44-118.93) ng/ml, respectively; p = 0.09) and survivors and nonsurvivors (86.14 ± 77.98 and 103.48 ± 69.92, respectively; p = 0.3). Although TAFI levels were lower in the patients with CCHF compared to healthy controls, it does not seem to be a major player in the prognosis.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Virus de la fièvre hémorragique de Crimée-Congo / Carboxypeptidase B2 / Fièvre hémorragique de Crimée-Congo Type d'étude: Etiology_studies / Prognostic_studies Limites: Adult / Humans Langue: En Journal: J Med Virol Année: 2023 Type de document: Article Pays d'affiliation: Turquie

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Virus de la fièvre hémorragique de Crimée-Congo / Carboxypeptidase B2 / Fièvre hémorragique de Crimée-Congo Type d'étude: Etiology_studies / Prognostic_studies Limites: Adult / Humans Langue: En Journal: J Med Virol Année: 2023 Type de document: Article Pays d'affiliation: Turquie